| Followers | 8 |
| Posts | 204 |
| Boards Moderated | 0 |
| Alias Born | 05/03/2006 |
Monday, May 03, 2021 9:24:31 AM
MDMA is also going to be big in new PTSD treatments: https: https://www.medpagetoday.com/meetingcoverage/apa/92379?xid=nl_mpt_DHE_2021-05-03&eun=g1330593d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202021-05-03&utm_term=NL_Daily_DHE_dual-gmail-definition
MindMed is currently trialing MDMA: //www.prnewswire.com/news-releases/mindmed-announces-the-start-of-the-first-ever-clinical-trial-combining-mdma-and-lsd-301211436.html
DOJI
MindMed is currently trialing MDMA: //www.prnewswire.com/news-releases/mindmed-announces-the-start-of-the-first-ever-clinical-trial-combining-mdma-and-lsd-301211436.html
DOJI
Recent DFTX News
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference • Business Wire • 05/21/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/19/2026 11:30:21 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 01:14:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 12:15:16 PM
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder • Business Wire • 05/12/2026 11:00:00 AM
- Definium Therapeutics Announces New Employee Inducement Grants • Business Wire • 05/11/2026 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:17:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:12:25 PM
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights • Business Wire • 05/07/2026 08:01:00 PM
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 • Business Wire • 04/30/2026 08:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/27/2026 08:07:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/27/2026 08:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 08:22:38 PM
- Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day • Business Wire • 04/22/2026 08:15:00 PM
- Definium Therapeutics Announces New Employee Inducement Grants • Business Wire • 04/20/2026 08:01:00 PM
- Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments • Business Wire • 04/18/2026 11:38:00 PM
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events • Business Wire • 04/09/2026 11:00:00 AM
- New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States • Business Wire • 03/31/2026 11:00:00 AM
- Definium Therapeutics Announces New Employee Inducement Grants • Business Wire • 03/30/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 10:43:44 PM
- Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 • Business Wire • 03/26/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/25/2026 09:41:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/25/2026 09:40:41 PM
- Definium Therapeutics Announces New Employee Inducement Grants • Business Wire • 03/09/2026 08:01:00 PM
- CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions • PR Newswire (Canada) • 03/09/2026 02:50:00 PM
